## Remarks

Claims 60-78 are pending in this application. Claim 1 is canceled without prejudice to Applicants' right to pursue the subject matter recited by them in one or more divisional, continuation or continuation-in-part applications. Claims 2-59 have been canceled without prejudice in a previous preliminary amendment filed November 25, 2003. Claims 60-78 are fully supported by the specification and claims as originally filed. Exemplary support for each pending claim is summarized in the table shown below. No new matter has been introduced.

Claim	Support	Claim	Support
60	Page 9, lines 5-7 Page 4, lines 8-14	61	Page 9, lines 5-7 Page 4, lines 8-14
62	Page 9, lines 5-7 Page 4, lines 8-14	63	Page 3, lines 2-3 Claims 1-3 Page 4, lines 8-14 Page 14, lines 25-28
64	Page 3, lines 2-3 Claims 1-3 Page 4, lines 8-14 Page 14, lines 12-28	65	Page 3, lines 2-3 Claims 1-3 Page 4, lines 8-14 Page 14, lines 12-28, in particular, line 12
66	Page 3, lines 2-3 Claims 1-3 Page 4, lines 8-14 Page 14, lines 12-28, in particular, line 12 Page 15, lines 1-3	67	Page 3, lines 2-3 Claims 1-3 Page 4, lines 8-14 Page 14, lines 12-28, in particular, line 12 Page 15, lines 4-35
68	Page 3, lines 2-3 Claims 1-3 Page 4, lines 8-14 Page 14, lines 12-28, in particular, line 12 Page 15, lines 4-35, in particular, lines 9-13	69	Page 3, lines 2-3 Claims 1-3 Page 4, lines 8-14 Page 14, lines 12-28, in particular, line 12 Page 15, lines 4-35, in particular, line 11
70	Page 3, lines 2-3 Claims 1-3 Page 4, lines 8-14 Page 14, lines 12-28, in particular, line 12 Page 17, lines 22-34	71	Page 3, lines 2-3 Claims 1-3 Page 4, lines 8-14 Page 14, lines 12-28, in particular, line 12 Page 17, lines 22-34, in particular, line 28

DCJD: 500633.1

72	Page 6, lines 3-7 Page 4, lines 16-18 Page 4, lines 8-14	73	Page 6, lines 3-7 Page 4, lines 16-18 Page 4, lines 8-14 Page 12, lines 36-38
74	Page 6, lines 3-7 Page 4, lines 16-18 Page 4, lines 8-14 Page 13, line1	75	Page 6, lines 3-7 Page 4, lines 16-18 Page 4, lines 8-14 Page 13, lines 1-2
76	Page 7, lines 28-32 Page 4, lines 8-14	77	Page 7, lines 23-27 Page 4, lines 8-14
78	Page 6, lines 3-7 and page 4, lines 16-18 (attention deficit disorder); page 6, lines 29-34 (autism and schizophrenia); page 6, lines 11-16 (obesity); page 7, lines 33-37 (anorexia and bulimia nervosa); page 7, lines 18-22 (cocaine and alcohol addiction); page 8, lines 6-12 (urinary incontinence); page 7, lines 8-12 (pain); page 6 lines 20-26 (Parkinson's disease and epilepsy); and page 4, lines 8-14		

Pursuant to 37 C.F.R. § 1.604(b), Applicants note that new claims 60-78 define the same patentable invention as claimed in U.S. Patent No. 6,673,838 B2, which issued to Hadfield *et al.* on January 6, 2004. Applicants also direct the Examiner's attention to their co-pending application, filed concurrently herewith, which also presents claims to the same patentable invention as claimed in U.S. Patent No. 6,637,838 B2.

No fee is believed due for this submission. If any fees are required, however, please charge such fee(s) to Jones Day Deposit Account No. 503013.

		Respectfully submitted,			
Date	March 23, 2004	Max Tarbant	45,479		
<del></del>		Max Bachrach	Reg. No.		
		Jones Day			
		51 Louisiana Avenue, N.W.			
		Washington, DC 20001-2113			
		(202) 879-3939			

For:

6

Jones Day 1155 Avenue of the Americas New York, New York 10036 (212) 790-9090

Thomas E. Friebel

DCJD: 500633.1

(Reg. No. 29,258)